TP53 and breast cancer: Foukakis et al. compared IRSN-23 with other diagnostic models, including ESR1, PIK3CA, and TP53, and reported a linear correlation between IRSN-23 and the four-month tumor shrinkage rate at metastatic sites, particularly in ER-positive, luminal-type breast cancer [22].